{"id":4565,"date":"2020-11-03T18:20:06","date_gmt":"2020-11-03T10:20:06","guid":{"rendered":"https:\/\/medicine.nus.edu.sg\/nuhscg\/?p=4565"},"modified":"2023-10-18T13:56:15","modified_gmt":"2023-10-18T05:56:15","slug":"an-industry-sponsored-randomized-double-blind-placebo-controlled-trial","status":"publish","type":"post","link":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/","title":{"rendered":"An industry-sponsored randomized, double-blind, placebo-controlled trial"},"content":{"rendered":"<p style=\"text-align: justify\"><img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone wp-image-162 size-full\" src=\"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/12\/example3-1.jpg\" alt=\"\" width=\"275\" height=\"183\" \/><\/p>\r\n<p>To participate, visit <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02585934?term=RVT101&amp;rank=2\" target=\"_blank\" rel=\"noopener noreferrer\">ClinicalTrials.gov<\/a> for registration!<\/p>\r\n<p style=\"text-align: justify\">Sponsor: Axovant Sciences Ltd<\/p>\r\n<h4 style=\"text-align: justify\">Research Aims<\/h4>\r\n<p style=\"text-align: justify\">The aims were to evaluate the efficacy of intepirdine (RVT-101) in combination with donepezil, compared to placebo, in patients with mild to moderate Alzheimer\u2019s disease.<\/p>\r\n<h4 style=\"text-align: justify\">How the Core Was Integral to the Study<\/h4>\r\n<ul style=\"text-align: justify\">\r\n\t<li>Recruited (14 patients in 6 months) and retained patients (100% retention rate) with Alzheimer\u2019s disease, who are very challenging to recruit and retain. Named the top recruitment site in Asia for this study.<\/li>\r\n\t<li>Obtained regulatory and safety approvals, as described in Project 1<\/li>\r\n\t<li>Performed the following assessments to help determine efficacy for cognitive function:\r\n\r\n<ul>\r\n\t<li>Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognitive 11 (ADAS-COG 11)<\/li>\r\n\t<li>Alzheimer&#8217;s Disease Co-operative Study &#8211; Activities of Daily Living (ADCS-ADL)<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t<li>Performed the following assessments to help determine efficacy for global functioning:\r\n\r\n<ul>\r\n\t<li>Clinician Interview-Based Impression of Change Plus (CIBIC+)<\/li>\r\n\t<li>EuroQol-5D (EQ-5D)<\/li>\r\n\t<li>Dependence Scale (DS)<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t<li>Performed the following scales to evaluate behavioural and mood symptoms\r\n\r\n<ul>\r\n\t<li>Neuropsychiatric Inventory (NPI)<\/li>\r\n\t<li>Columbia-Suicide Severity Rating Scale (C-SSRS)<\/li>\r\n<\/ul>\r\n<\/li>\r\n\t<li>Performed the following assessments to assess the caregiver burden\r\n\r\n<ul>\r\n\t<li>Resource Utilization in Dementia-lite (RUD-lite)<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<h4 style=\"text-align: justify\">Results<\/h4>\r\n<p style=\"text-align: justify\">Intepirdine, in combination with donepezil, was not more effective than placebo for patients with mild to moderate Alzheimer\u2019s disease.<\/p>\r\n<h4>Find out more!<\/h4>\r\n<p>Visit our <a href=\"https:\/\/medicine.nus.edu.sg\/nuhscg\/core-facilities\/neurocognitive-core\/menu-of-services\/\" target=\"_blank\" rel=\"noopener noreferrer\">Menu of Services<\/a> page to find out more about our services and prices.<\/p>","protected":false},"excerpt":{"rendered":"To participate, visit ClinicalTrials.gov for registration! Sponsor: Axovant Sciences Ltd Research Aims The aims were to evaluate the efficacy of intepirdine (RVT-101) in combination with donepezil, compared to placebo, in patients with mild to moderate Alzheimer\u2019s disease. How the Core Was Integral to the Study Recruited (14 patients in 6&#8230;","protected":false},"author":4,"featured_media":4293,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50,26,1],"tags":[],"class_list":["post-4565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-example-projects-neurocognitive-core","category-neurocognitive-core","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>An industry-sponsored randomized, double-blind, placebo-controlled trial | Example Projects, Neurocognitive Core, News | NUHS Centre Grant - Singapore Core Facilities for Diabetes, Infectious Diseases and Neuroscience<\/title>\n<meta name=\"description\" content=\"The aims were to evaluate the efficacy of intepirdine (RVT-101) in combination with donepezil, compared to placebo, in patients with mild to moderate Alzheimer\u2019s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"An industry-sponsored randomized, double-blind, placebo-controlled trial | Example Projects, Neurocognitive Core, News | NUHS Centre Grant - Singapore Core Facilities for Diabetes, Infectious Diseases and Neuroscience\" \/>\n<meta property=\"og:description\" content=\"The aims were to evaluate the efficacy of intepirdine (RVT-101) in combination with donepezil, compared to placebo, in patients with mild to moderate Alzheimer\u2019s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"NUHS Centre Grant\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-03T10:20:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-18T05:56:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/10\/NUS-YLLSoM.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1035\" \/>\n\t<meta property=\"og:image:height\" content=\"1035\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/\",\"url\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/\",\"name\":\"An industry-sponsored randomized, double-blind, placebo-controlled trial | Example Projects, Neurocognitive Core, News | NUHS Centre Grant - Singapore Core Facilities for Diabetes, Infectious Diseases and Neuroscience\",\"isPartOf\":{\"@id\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/10\/NUS-YLLSoM.jpg\",\"datePublished\":\"2020-11-03T10:20:06+00:00\",\"dateModified\":\"2023-10-18T05:56:15+00:00\",\"author\":{\"@id\":\"\"},\"description\":\"The aims were to evaluate the efficacy of intepirdine (RVT-101) in combination with donepezil, compared to placebo, in patients with mild to moderate Alzheimer\u2019s disease.\",\"breadcrumb\":{\"@id\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#primaryimage\",\"url\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/10\/NUS-YLLSoM.jpg\",\"contentUrl\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/10\/NUS-YLLSoM.jpg\",\"width\":1035,\"height\":1035},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"An industry-sponsored randomized, double-blind, placebo-controlled trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/#website\",\"url\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/\",\"name\":\"NUHS Centre Grant\",\"description\":\"Singapore Core Facilities for Diabetes, Infectious Diseases and Neuroscience\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/medicine.nus.edu.sg\/nuhscg\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"An industry-sponsored randomized, double-blind, placebo-controlled trial | Example Projects, Neurocognitive Core, News | NUHS Centre Grant - Singapore Core Facilities for Diabetes, Infectious Diseases and Neuroscience","description":"The aims were to evaluate the efficacy of intepirdine (RVT-101) in combination with donepezil, compared to placebo, in patients with mild to moderate Alzheimer\u2019s disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/","og_locale":"en_US","og_type":"article","og_title":"An industry-sponsored randomized, double-blind, placebo-controlled trial | Example Projects, Neurocognitive Core, News | NUHS Centre Grant - Singapore Core Facilities for Diabetes, Infectious Diseases and Neuroscience","og_description":"The aims were to evaluate the efficacy of intepirdine (RVT-101) in combination with donepezil, compared to placebo, in patients with mild to moderate Alzheimer\u2019s disease.","og_url":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/","og_site_name":"NUHS Centre Grant","article_published_time":"2020-11-03T10:20:06+00:00","article_modified_time":"2023-10-18T05:56:15+00:00","og_image":[{"width":1035,"height":1035,"url":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/10\/NUS-YLLSoM.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/","url":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/","name":"An industry-sponsored randomized, double-blind, placebo-controlled trial | Example Projects, Neurocognitive Core, News | NUHS Centre Grant - Singapore Core Facilities for Diabetes, Infectious Diseases and Neuroscience","isPartOf":{"@id":"https:\/\/medicine.nus.edu.sg\/nuhscg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#primaryimage"},"image":{"@id":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/10\/NUS-YLLSoM.jpg","datePublished":"2020-11-03T10:20:06+00:00","dateModified":"2023-10-18T05:56:15+00:00","author":{"@id":""},"description":"The aims were to evaluate the efficacy of intepirdine (RVT-101) in combination with donepezil, compared to placebo, in patients with mild to moderate Alzheimer\u2019s disease.","breadcrumb":{"@id":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#primaryimage","url":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/10\/NUS-YLLSoM.jpg","contentUrl":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-content\/uploads\/sites\/6\/2019\/10\/NUS-YLLSoM.jpg","width":1035,"height":1035},{"@type":"BreadcrumbList","@id":"https:\/\/medicine.nus.edu.sg\/nuhscg\/an-industry-sponsored-randomized-double-blind-placebo-controlled-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medicine.nus.edu.sg\/nuhscg\/"},{"@type":"ListItem","position":2,"name":"An industry-sponsored randomized, double-blind, placebo-controlled trial"}]},{"@type":"WebSite","@id":"https:\/\/medicine.nus.edu.sg\/nuhscg\/#website","url":"https:\/\/medicine.nus.edu.sg\/nuhscg\/","name":"NUHS Centre Grant","description":"Singapore Core Facilities for Diabetes, Infectious Diseases and Neuroscience","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medicine.nus.edu.sg\/nuhscg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"","url":"https:\/\/medicine.nus.edu.sg\/nuhscg\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/posts\/4565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/comments?post=4565"}],"version-history":[{"count":2,"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/posts\/4565\/revisions"}],"predecessor-version":[{"id":4567,"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/posts\/4565\/revisions\/4567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/media\/4293"}],"wp:attachment":[{"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/media?parent=4565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/categories?post=4565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/nuhscg\/wp-json\/wp\/v2\/tags?post=4565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}